Jump to navigation Jump to search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Alizapride


Most recent articles on Alizapride

Most cited articles on Alizapride

Review articles on Alizapride

Articles on Alizapride in N Eng J Med, Lancet, BMJ


Powerpoint slides on Alizapride

Images of Alizapride

Photos of Alizapride

Podcasts & MP3s on Alizapride

Videos on Alizapride

Evidence Based Medicine

Cochrane Collaboration on Alizapride

Bandolier on Alizapride

TRIP on Alizapride

Clinical Trials

Ongoing Trials on Alizapride at Clinical

Trial results on Alizapride

Clinical Trials on Alizapride at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alizapride

NICE Guidance on Alizapride


FDA on Alizapride

CDC on Alizapride


Books on Alizapride


Alizapride in the news

Be alerted to news on Alizapride

News trends on Alizapride


Blogs on Alizapride


Definitions of Alizapride

Patient Resources / Community

Patient resources on Alizapride

Discussion groups on Alizapride

Patient Handouts on Alizapride

Directions to Hospitals Treating Alizapride

Risk calculators and risk factors for Alizapride

Healthcare Provider Resources

Symptoms of Alizapride

Causes & Risk Factors for Alizapride

Diagnostic studies for Alizapride

Treatment of Alizapride

Continuing Medical Education (CME)

CME Programs on Alizapride


Alizapride en Espanol

Alizapride en Francais


Alizapride in the Marketplace

Patents on Alizapride

Experimental / Informatics

List of terms related to Alizapride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Alizapride (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.[1]

See also

This image is provided by the National Library of Medicine.


  1. Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M (1988). "Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial". Cancer Chemother Pharmacol. 22 (4): 316–20. doi:10.1007/bf00254238. PMID 3048762.